TREM2 might represent an attractive therapeutic target in cardiometabolic disease, as, in addition to its proposed beneficial roles in obesity and other lipid-driven diseases, such as NASH, activating TREM2 signaling may limit plaque necrosis and promote stabilization of atherosclerotic lesions. This evidence concerns the gene TREM2 and metabolic dysfunction-associated steatohepatitis.